Worldwide Cancer Generics Industry Insights, 2018-2026: Comprehensive Insights on 43 Drugs & 29 Players

DUBLIN, March 5, 2020 /PRNewswire/ -- The "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This research report provides an in-depth analysis about the trends that are followed by the cancer generics market at the global and regional level as well as the revolutionizing strategies that have been adopted and supported by the governing and regulatory bodies around the globe.

The study is a result of the extensive study conducted by analyzing the global companies for cancer generics. The opinions from the different generic drug companies have been gathered to successfully deliver the latest trends and opportunities and the future prospects on commercials for the market of cancer generics.

The report highlights:

    --  Global Cancer Generics Market Trend Analysis
    --  Global Cancer Generics Market Opportunity: > USD 55 Billion by 2026
    --  Global Generics Market Growth 2018-2026: > 130%
    --  Global Cancer Generics Market Growth 2018-2026: 200%
    --  Reimbursement Policies & the Coverage Strategies by Countries
    --  Cancer Generic Drugs Availability, Dosage & Price Analysis by Segment
    --  Comprehensive Insight on Cancer Generics Drugs: 43 Generics

Since the arrival of the generic drugs approach 30 years ago, the market is showing a tremendous elevation in the consumption rate of the cancer generics across the globe: the reasons being the uncontrollably growing population and the unmanageable crisis of cancer mortality. The major advantage that is largely associated with the accelerated generics drug market is the fact that the development of the drug doesn't require prolonged period of time. The ease in developing the drug and the high adoption rate by the patients contribute largely to the established markets of cancer generics.

Global Cancer Generic Drug Market to Witness Exponential Growth as Drug Sales are Expected to Increase Beyond US$ 55 Billion by 2026

It is well-witnessed fact that the survival rate of the cancer patients have experienced a positive trail since the advent of the cancer generic drugs in the market. Patients and clinicians, whenever possible are more inclined towards the utilization of generic drugs in their treatment, as it is more segmented towards the patients that are not able to consume branded drugs, which however comprises of the maximum population around the globe. The necessity of generic drugs in the society and the upsurge it has been experiencing since its arrival at the global pharmaceutical landscape represents a stage of the market which is highly dominated by the cancer generics drugs.

Cancer generics market gets highlighted by the minimal efforts drug makers have to put and the maximum advantages that the patients will receive. The most important and the fundamental advantages that are received by the approach is that it provides the bioequivalent form of the original branded drug i.e. in same dosage, mode of administration and the effectiveness in a way cheaper price. Such advantages are making the whole percentage of patients with no or less hope towards a more suitable and decent method by providing a privileged from of treatment.

The increasing consumption of generic drugs and the mounting trust of patient towards cancer generics drugs are going to play a very important role in the market expansion. A big contribution for the splendid market growth rate is also provided by the governing bodies of the respective country. The impositions made by the governing bodies for clinicians in dispensing generic drugs have caused an accelerated growth in the market size. The market of cancer generics is also escalating by the fact that the number of pharmaceuticals players interested in manufacturing generic drugs have been increasing.

Key Topics Covered

1. Introduction to Cancer Generics
1.1 Overview
1.2 The Growing Need for Cancer Generics over Branded Drugs
1.2.1 Reduced Developmental Cost Leading to Cost-Efficient Cancer Generics
1.2.2 Reduced Timeline Leading to Cost-Efficient Cancer Generics Development
1.2.3 Cancer Generics Representing Same Effectiveness as of Branded Drugs

2. Global Cancer Generics Market Trend Analysis
2.1 Overview
2.2 Current Market Scenario
2.3 Cancer Generics Market Future Outlook

3. US - Current Market Status of Cancer Generics
3.1 Significant Facts & Figures Prevailing Cancer Generics Market
3.2 US Cancer Generics Market Trends & Opportunities
3.2.1 Guidelines, Policies & Procedures by the FDA for the US Market

4. Japan - Current Cancer Generics Market Insight
4.1 Factors Propelling the Growth of Cancer Generics in Japan
4.2 Trends & Opportunities of Cancer Generics Market in Japan
4.2.1 Cancer Generic Drugs Prescription & Dispensing

5. Europe - Key Asset to Cancer Generics Market Progression
5.1 Evaluation of Facts Associated with Cancer Generics Growth
5.2 Cancer Generics Market Current Trends & Opportunities
5.2.1 Europe Government Regulations for Cancer Generics Market Progress
5.2.2 Germany - Current Cancer Generics Market Trends & Opportunities
5.2.3 France - Current Cancer Generics Market Trends & Opportunity
5.2.4 UK - Current Cancer Generics Market Trends & Opportunities
5.2.5 Belgium - Current Cancer Generics Market Trends & Opportunities
5.2.6 Others - Current Cancer Generics Market Trends & Opportunities

6. China - As an Emerged Cancer Generic Market in Asia
6.1 Simulating Facts & Figures for Chinese Cancer Generics Market
6.2 Trends & Opportunities Linked with China's Cancer Generics Market
6.2.1 Laws & Regulating Supporting Cancer Generics Market in China

7. India - A Major Contributor to the Global Generics Market
7.1 Fact Sheets Related to Cancer Generics Growth in India
7.2 Trends & Opportunities for India's Cancer Generics Market
7.2.1 Guidelines & Laws for Implementing Generic Drugs in India

8. South Korea - Cancer Generics Market Current Insight
8.1 Cancer Generics Drug Market Expansion Facts & Figures
8.2 Provoking Trends & Opportunities for South Korean Cancer Generics Market

9. Russia - Cancer Generics Market Scenario
9.1 Facts Encouraging the Current Market Situation in Russia
9.2 Trends & Opportunities Followed by Russian Cancer Generics Market
9.2.1 Rules & Regulations Boosting the Current Market of Cancer Generics

10. Reimbursement Policies & the Coverage Strategies
10.1 U.S.
10.2 Europe
10.3 India
10.4 Japan
10.5 China
10.6 Russia

11. Price Analysis for Branded Drugs vs. Generic Drugs

12. Breast Cancer Generic Drugs - Availability, Dosage & Price Analysis
12.1 Letrozole
12.2 Anastrazole
12.3 Exemestane
12.4 Epirubicine
12.5 Toremifene
12.6 Fulvestrant
12.7 Megestrol

13. Colorectal Cancer Generic Drugs - Availability, Dosage & Price Analysis
13.1 Irinotecan
13.2 Oxaliplatin

14. Leukemia Generic Drugs - Availability, Dosage & Price Analysis
14.1 Clofarabin
14.2 Imatinib
14.3 Mercaptopurine
14.4 Idarubicin
14.5 Daunorubicin
14.6 Cytarabin

15. Prostate Cancer Generic Drugs - Availability, Dosage & Price Analysis
15.1 Abiraterone
15.2 Bicalutamide
15.3 Nilutamide
15.4 Flutamide

16. Skin Cancer Generic Drugs - Availability, Dosage & Price Analysis
16.1 Imiquimod Topical Cream
16.2 Fluorouracil Topical

17. Lung Cancer Generic Drugs - Availability, Dosage & Price Analysis
17.1 Vinorelbine

18. Brain Tumor Generic Drugs - Availability, Dosage & Price Analysis
18.1 Temozolomide

19. Renal Cell Carcinoma Generic Drug - Availability, Dosage & Price Analysis
19.1 Temsirolimus

20. Generic Drugs for Multiple Cancers - Availability, Dosage & Price Analysis
20.1 Erlotinib
20.2 Dactinomycin
20.3 Ifosfamide
20.4 Romidepsin
20.5 Everolimus
20.6 Capecitabine
20.7 Gemcitabine
20.8 Paclitaxel
20.9 Fluorouracil
20.10 Docetaxel
20.11 Methotrexate
20.12 Cyclophosphamide
20.13 Vincristine
20.14 Etoposide
20.15 Mitoxantrone
20.16 Carmustine
20.17 Dacarbazine
20.18 Mitomycin
20.19 Bleomycin

21. Global Cancer Generics Market Dynamics
21.1 Factors Favoring the Growth of Cancer Generics Market
21.2 Factors Restraining the Growth of Cancer Generics Market

22. Competitive Landscape
22.1 Teva Pharmaceuticals
22.2 Accord Healthcare
22.3 Amneal Pharmaceuticals
22.4 Mylan
22.5 Dr. Reddy Laboratories
22.6 Bedford Pharma
22.7 Hikma
22.8 Cipla
22.9 Shilpa Medicare
22.10 Fresenius Kabi
22.11 Zydus Pharmaceuticals
22.12 Neopharm
22.13 Netco
22.14 Mayne Pharma
22.15 Alvogen
22.16 Glenmark
22.17 HBT Labs
22.18 Gland
22.19 Qilu Pharmaceuticals
22.20 Akorn Pharmaceuticals
22.21 MSN Group
22.22 Wockhardt
22.23 Rising Pharma
22.24 Apotex
22.25 Taro Pharmaceuticals
22.26 Sun Pharma
22.27 Alkem Laboratories
22.28 Endo Pharma
22.29 Pfizer (Hospira)

For more information about this report visit https://www.researchandmarkets.com/r/4dgndi

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/worldwide-cancer-generics-industry-insights-2018-2026-comprehensive-insights-on-43-drugs--29-players-301017401.html

SOURCE Research and Markets